- Home
- MDCX vs GSIW Comparison
MDCX vs GSIW Comparison
Compare MDCX & GSIW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | MDCX | GSIW |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.1M | 28.6M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MDCX | GSIW |
|---|---|---|
| Price | $0.95 | $0.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | 375.5K | ★ 536.0K |
| Earning Date | 03-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,087,497.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 515.58 |
| 52 Week Low | $0.99 | $0.09 |
| 52 Week High | $8.94 | $1.79 |
Technical Indicators
Market Signals| Indicator | MDCX | GSIW |
|---|---|---|
| Relative Strength Index (RSI) | 21.00 | 49.89 |
| Support Level | $1.09 | $0.11 |
| Resistance Level | $1.29 | $0.16 |
| Average True Range (ATR) | 0.12 | 0.01 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 1.17 | 69.46 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.